To amend the Public Health Service Act to establish a program to develop innovative antimicrobial drugs targeting the most challenging pathogens and most threatening infections, and for other purposes.

H.R. 7352 would amend the Public Health Service Act to create a program focused on developing innovative antimicrobial drugs targeting the most challenging pathogens and threatening infections. The bill, introduced by Representative Buddy Carter (R-GA) in February 2026, is currently under committee consideration and has not yet been voted on by the full House.

If enacted, this legislation would establish a framework to accelerate the development of new antibiotics and antimicrobial treatments for infections that are particularly difficult to treat or pose significant public health threats. This could include drugs targeting antibiotic-resistant bacteria and other hard-to-treat pathogens. The practical impact would depend on the program's specific funding, structure, and implementation details, which would be determined as the bill moves through the legislative process.

The bill represents an effort to address antimicrobial resistance and infectious disease challenges through federal support for drug development, though its current status as a referred bill means its ultimate scope and provisions may change during committee review.